Novozymes As B Stock Revenue
NVZMF Stock | USD 54.45 1.74 3.30% |
Novozymes AS B fundamentals help investors to digest information that contributes to Novozymes' financial success or failures. It also enables traders to predict the movement of Novozymes Pink Sheet. The fundamental analysis module provides a way to measure Novozymes' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novozymes pink sheet.
Novozymes |
Novozymes AS B Company Revenue Analysis
Novozymes' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Novozymes Revenue | 17.55 B |
Most of Novozymes' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novozymes AS B is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition |
Based on the latest financial disclosure, Novozymes AS B reported 17.55 B of revenue. This is 123.35% higher than that of the Basic Materials sector and 294.44% higher than that of the Specialty Chemicals industry. The revenue for all United States stocks is 86.04% lower than that of the firm.
Novozymes Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novozymes' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novozymes could also be used in its relative valuation, which is a method of valuing Novozymes by comparing valuation metrics of similar companies.Novozymes is currently under evaluation in revenue category among related companies.
Novozymes Fundamentals
Return On Equity | 0.28 | |||
Return On Asset | 0.11 | |||
Profit Margin | 0.21 % | |||
Operating Margin | 0.26 % | |||
Current Valuation | 14.47 B | |||
Shares Outstanding | 222.86 M | |||
Shares Owned By Insiders | 8.04 % | |||
Shares Owned By Institutions | 42.30 % | |||
Price To Earning | 33.38 X | |||
Price To Book | 6.19 X | |||
Price To Sales | 0.82 X | |||
Revenue | 17.55 B | |||
Gross Profit | 9.59 B | |||
EBITDA | 6.12 B | |||
Net Income | 3.68 B | |||
Cash And Equivalents | 1.01 B | |||
Cash Per Share | 3.67 X | |||
Total Debt | 7.31 B | |||
Debt To Equity | 0.58 % | |||
Current Ratio | 1.20 X | |||
Book Value Per Share | 50.02 X | |||
Cash Flow From Operations | 4.01 B | |||
Earnings Per Share | 1.90 X | |||
Price To Earnings To Growth | 3.85 X | |||
Target Price | 28.3 | |||
Number Of Employees | 6.44 K | |||
Beta | 0.4 | |||
Market Capitalization | 13.95 B | |||
Total Asset | 27.98 B | |||
Retained Earnings | 9.99 B | |||
Working Capital | 2.67 B | |||
Current Asset | 6.08 B | |||
Current Liabilities | 3.41 B | |||
Z Score | 0.6 | |||
Annual Yield | 0.02 % | |||
Five Year Return | 1.38 % | |||
Net Asset | 27.98 B | |||
Last Dividend Paid | 6.0 |
About Novozymes Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novozymes AS B's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novozymes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novozymes AS B based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novozymes in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novozymes' short interest history, or implied volatility extrapolated from Novozymes options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS B. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |